Successful EUR 50 Million Capital Increase
ONWARD Medical N.V. has made headlines by successfully raising EUR 50 million through an upsized private placement aimed at expanding its innovative spinal cord stimulation therapies. This significant capital increase will support the company's commitment to restoring movement and function for individuals affected by spinal cord injuries (SCI). With strong backing from prominent investors, including Ottobock SE & Co. KGaA, the future is looking brighter for ONWARD Medical's mission.
Strategic Investment from Ottobock
The involvement of Ottobock as a cornerstone investor marks a pivotal moment for ONWARD Medical. The German company, known for its leadership in prosthetic and orthotic technology, will acquire approximately 10% of ONWARD's share capital. This strategic relationship is built on shared values and a mutual goal to innovate solutions for patients experiencing paralysis and mobility issues.
Impacts of the Investment
According to CEO Dave Marver, this funding will significantly enhance ONWARD Medical’s cash runway, extending it to two years or more. The company is well-positioned to commercialize its groundbreaking ARC-EX System and to further pioneer the development of its other investigational therapies. This partnership promises collaboration opportunities that could lead to accelerated advancements in treatments aimed at restoring independence to those with movement disabilities.
Commitment to Research and Development
ONWARD Medical plans to utilize the raised funds primarily for continued research and development. This includes initiatives focused on the investigational ARC-IM® System, which targets improved blood pressure regulation after SCI, along with the ARC-BCI™ System designed to restore thought-driven movements for those facing severe mobility limitations. Investment in clinical studies and regulatory activities will play a vital role in bringing these innovative solutions to market.
Enhancing Commercial Launch Efforts
The financing will also facilitate an expected commercial launch of the ARC-EX System in the United States. This launch will involve developing a field sales organization and conducting extensive training events, along with engaging in customer support activities that are essential for market success.
Infrastructure Development
Furthermore, a portion of the funds will be allocated to build ONWARD's operational capabilities, ensuring quality and administrative support align with the anticipated growth. These efforts are geared towards creating a sustainable environment that fosters innovation and maintains competitive advantages in the market.
Financial Overview and Market Presence
The private placement comes at a crucial time for ONWARD Medical, given its recent achievements in clinical trials, particularly in demonstrating the effectiveness of its therapies, evidenced by significant improvements in upper limb function through non-invasive ARC-EX therapy. The company is also actively submitting regulatory applications, seeking FDA approval for its breakthrough solutions, and preparing for corresponding regulatory submissions in Europe.
Market Strategy and Future Prospects
The reception to ONWARD Medical's offer during the bookbuilding period was strong, reflecting investors' confidence in the company's future potential. With planned admissions of the newly issued shares to trading on various European exchanges, including Euronext Brussels, Euronext Amsterdam, and Euronext Paris, ONWARD is poised to enhance its market presence significantly.
Commitment to Innovation
As ONWARD continues to make strides in spinal cord injury therapies, partnerships with entities like Ottobock will be crucial. The collaboration aims to leverage Ottobock’s century of experience in biomechanics to enhance therapeutic outcomes and support innovative development.
About ONWARD Medical
ONWARD Medical is dedicated to creating transformative therapies for individuals experiencing spinal cord injury and related disabilities. With innovative approaches backed by rigorous scientific research, ONWARD's ARC Therapy has already received multiple Breakthrough Device Designations from regulatory bodies.
Frequently Asked Questions
What is ONWARD Medical known for?
ONWARD Medical focuses on developing therapies that restore movement and function for individuals with spinal cord injuries.
Who is the cornerstone investor for ONWARD Medical?
Ottobock SE & Co. KGaA is the cornerstone investor and has acquired approximately 10% of ONWARD Medical's share capital.
How will ONWARD Medical use the raised funds?
The funds will be utilized for research and development, commercial launch efforts, operational improvements, and working capital requirements.
What products are involved in ONWARD Medical's strategy?
Key products include the ARC-EX® System, ARC-IM® System, and ARC-BCI™ System, each aimed at addressing different aspects of SCI rehabilitation.
Where is ONWARD Medical headquartered?
ONWARD Medical is headquartered in Eindhoven, the Netherlands, with additional facilities in Lausanne, Switzerland, and Boston, Massachusetts.
